In VitroandIn VivoActivities of Tigecycline-Colistin Combination Therapies against Carbapenem-Resistant Enterobacteriaceae

Abstract

ABSTRACTWe assessed the activity of tigecycline (TGC) combined with colistin (COL) against carbapenem-resistant enterobacteria. Synergy occurredin vitroagainst the majority of isolates, with the exception ofSerratia marcescens. In a simple animal model (Galleria mellonella), TGC-COL was superior (P< 0.01) in treatingEscherichia coli,Klebsiella pneumoniae, andEnterobacterinfections, including those with TGC-COL resistance. Clinical studies are needed to determine whether TGC-COL regimens may be a viable option.